Better Therapeutics announced it has submitted a request to the FDA for breakthrough device designation for its novel PDT designed to treat metabolic dysfunction-associated steatotic liver disease, or MASLD, and metabolic dysfunction-associated steatohepatitis, or MASH, formerly known as NAFLD and NASH.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BTTX:
- Better Therapeutics files to sell 20M shares of common stock for holders
- Better Therapeutics strengthens financials with amendment to debt, costs
- Better Therapeutics reports Q3 EPS (15c), consensus (21c)
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue